Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Henlius Biotech (2696 HK)
Watchlist
70
Analysis
Health Care
•
China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Shanghai Henlius Biotech
•
02 May 2024 19:34
•
Broker
Henlius Biotech (2696 HK) - Strong Product Sales in 1Q
Strong sales maintained in 1Q24. Henlius Biotech (Henlius) recorded total revenue of RMB1.349bn in 1Q24, up 35% YoY. Of this, HANQUYOU’s sales in...
CMB International
Follow
134 Views
Share
bullish
•
Shanghai Henlius Biotech
•
25 Mar 2024 20:52
•
Broker
Henlius Biotech (2696 HK) - Anticipating Sustained Profitability
Henliu’s FY23 revenue increased 67.8% YoY to RMB5.40bn, driven by strong sales of HANQUYOU (trastuzumab biosimilar) and serplulimab (PD-1).
CMB International
Follow
143 Views
Share
bullish
•
Shanghai Henlius Biotech
•
22 Jan 2024 10:11
•
Broker
Henlius Biotech (2696 HK) – Promising Ph2 Data of Innovative Assets
In the study, a total of 53 patients were randomized to Group A (HLX22 25mg/kg + Hanquyou + chemo), Group B (HLX22 15mg/kg + Hanquyou + chemo) and...
CMB International
Follow
228 Views
Share
bullish
•
Shanghai Henlius Biotech
•
29 Aug 2023 09:13
•
Broker
Henlius Biotech (2696 HK) – Profit Turnaround in 1H23
Henlius’ 1H23 revenue increased 94% YoY to RMB2.50bn, mainly driven by the strong sales growth of HANQUYOU (trastuzumab biosimilar) and HANSIZHUANG...
CMB International
Follow
136 Views
Share
bullish
•
Akeso Biopharma Inc
•
16 Apr 2024 23:56
[Blue Lotus Healthcare Sector Update]: Bottom-Fishing at the Bottom of the Business Cycle
Liquidity crises in healthcare innovation present buying opportunity;PD-1 exceeds expectations with 20%YoY growth forecast for 2024;Biosimilars...
Blue Lotus Research Institute
Follow
191 Views
Share
1
2
3
4
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.31.1
x